Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Atorvastatin + phenytoin** is a pharmacological combination of two small molecule drugs: atorvastatin, an HMG-CoA reductase inhibitor (statin) used primarily to lower cholesterol and reduce cardiovascular risk, and phenytoin, an antiepileptic medication primarily used for the management and prevention of seizures. Atorvastatin acts by inhibiting hepatic cholesterol synthesis via competitive inhibition of HMG-CoA reductase, resulting in upregulation of LDL receptors and increased clearance of LDL cholesterol. Phenytoin acts mainly by stabilizing neuronal membranes and reducing repetitive neuronal firing by promoting sodium efflux from neurons. When administered together, phenytoin, a potent CYP3A4 inducer, reduces the serum concentration and efficacy of atorvastatin by increasing its metabolic clearance[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + phenytoin.